Leading Clinical Trials
Sarah Cannon Research Institute is the research arm of HCA Healthcare's cancer institute, Sarah Cannon, and has led more than 400 first-in-human clinical trials to date. We have been a clinical trial leader in the majority of approved cancer therapies over the last decade.
Outside of leading clinical trials, HCA Healthcare offers integrated cancer services with convenient access to cutting-edge therapies for people facing cancer in communities across the United States and United Kingdom. Sarah Cannon’s cancer programs include individualized patient navigation provided by oncology-trained nurses, nearly 1,200 stem cell transplants performed annually throughout the Sarah Cannon Blood Cancer Network, hundreds of clinical trial options, and molecular profiling capabilities. Sarah Cannon also offers a helpline, askSARAH, so that people with cancer questions can talk to a specially trained nurse to receive trusted information. Through its services, Sarah Cannon is providing state-of-the-art cancer care close to home for hundreds of thousands of patients, a number unmatched by any single cancer center.
Leader in the majority of approved cancer therapies.
400 first-in-human clinical trials to date.
- NPR: In A 1st, Doctors In U.S. Use CRISPR Tool To Treat Patient With Genetic Disorder
HCA Healthcare’s Sarah Cannon Research Institute is developing innovative ways of treating sickle cell disease and is only 1 of 8 sites in the world to enroll patients in this trial.